MedTrace Logo

Safety and Immunogenicity of Vi-DT Typhoid Conjugate Vaccine in Indonesian Adults, Adolescents, Children and Infants

NCT03460405 · Status: COMPLETED · Phase: PHASE2 · Type: INTERVENTIONAL · Enrollment: 600

Last updated 2020-02-20

No results posted yet for this study

Summary

This study is to assess the safety and immunogenicity of Vi-DT vaccine in adults, adolescent, children and infants.

Conditions

  • Safety Issues
  • Immunogenicity

Interventions

BIOLOGICAL

Vi-DT Vaccine

1 dose of Vi-DT Vaccine

BIOLOGICAL

Vi Polysaccharide Vaccine

1 dose of Vi Polysaccharide Vaccine

BIOLOGICAL

IPV Vaccine

1 dose of IPV Vaccine

Sponsors & Collaborators

  • PT Bio Farma

    lead INDUSTRY

Principal Investigators

  • Bernie Endyarni, MD · Faculty of Medicine, University of Indonesia

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
DOUBLE
Model
PARALLEL

Eligibility

Min Age
6 Months
Max Age
40 Years
Sex
ALL
Healthy Volunteers
Yes

Timeline & Regulatory

Start
2018-07-16
Primary Completion
2019-12-31
Completion
2020-01-30

Countries

  • Indonesia

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT03460405 on ClinicalTrials.gov